Pfizer reports 25-valent vaccine data. November 3 results guide Pfizer stock

Published on 10/26/2026 at 11:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The vaccine candidate covered all 25 serotypes after four doses. Pfizer stock costs EUR 26.83 on October 26, 2026 versus EUR 26.89 at the Xetra close.

Pipeline and earnings calendar

Pfizer reported Phase 2 results on October 24, 2026, covering all 25 vaccine serotypes.
Second-quarter revenue reached USD 15.03 billion, up 2.60 percent year over year.
Pfizer stock traded at EUR 26.83 at 11:47 a.m. CET at Lang & Schwarz on October 26, 2026, 0.22 percent below the Xetra close of October 23, 2026.
Pfizer's next earnings event is scheduled for November 3, 2026.

Pfizer Inc., US7170811035, Illustration mit AI erstellt.

Pfizer Inc. (ISIN US7170811035) was trading at EUR 26.83 at Lang & Schwarz on October 26, 2026, at 11:47 a.m. CET, 0.22 percent below the Xetra close of October 23, 2026 at EUR 26.89. The company reported detailed Phase 2 results for its investigational 25-valent pneumococcal vaccine candidate on October 24, 2026, while November 3, 2026 is the next earnings date listed by Pfizer.

According to Pfizer, a four-dose series of PF-07872412 generated immune responses against all 25 serotypes in healthy infants. Safety and tolerability were comparable with four doses of PREVNAR 20, and the data were presented at IDWeek 2026 in Washington, D.C.

Three dates shape the pipeline

The chronology shows how Pfizer's near-term story has moved from cash returns to pipeline development. On August 4, 2026, Pfizer reported second-quarter revenue of USD 15.03 billion and adjusted earnings per share of USD 0.77, with revenue up 2.60 percent year over year, according to MarketBeat. On October 6, 2026, Pfizer declared a quarterly dividend of USD 0.43 per common share, as reported by Yahoo Finance. On October 24, 2026, the company published the 25-serotype vaccine findings, making the clinical program the latest dated development.

What could move Pfizer next?

The next scheduled event is Pfizer's earnings webcast on November 3, 2026, followed by the November 6, 2026 ex-dividend date listed by MarketBeat. The company's fiscal 2026 adjusted earnings guidance remains USD 2.80 to USD 3.00 per share, while Erste Group Bank reduced its fiscal 2026 estimate from USD 2.97 to USD 2.96 per share in a report dated October 21, 2026, according to MarketBeat. That forecast sits below Pfizer's guidance midpoint of USD 2.90.

Stock stays below the recent range high

The euro quotation sits inside its 52-week range of EUR 20.72 to EUR 27.12. For investors, the November earnings date offers the next test of whether pipeline progress can offset pressure on post-pandemic revenue and cash distribution.

Pfizer stock was trading at EUR 26.83 at Lang & Schwarz on October 26, 2026, at 11:47 a.m. CET, 0.22 percent below the Xetra close of October 23, 2026 at EUR 26.89. The further course of trading is shown by the continuously updated real-time quote of Pfizer stock.